IJCP Editorial Team
US FDA Approves Anti-Cancer Injection
Alembic Pharmaceuticals gained approval for Docetaxel Injection use from the US Food & Drug Administration (USFDA).
The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product (RLD) – Docetaxel Injection, 20 mg/2 mL, 80 mg/8 mL, and 160 mg/16 mL (10 mg/mL), of Hospira, Inc.
Docetaxel belongs to the ‘taxanes’ drug class that inhibits cancer progression and spread. This drug targets breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of the head and neck. IQVIA estimated its market worth in 2022 - US$ 11 million for twelve months.
IJCP Editorial Team
Comprising seasoned professionals and experts from the medical field, the IJCP editorial team is dedicated to delivering timely and accurate content and thriving to provide attention-grabbing information for the readers. What sets them apart are their diverse expertise, spanning academia, research, and clinical practice, and their dedication to upholding the highest standards of quality and integrity. With a wealth of experience and a commitment to excellence, the IJCP editorial team strives to provide valuable perspectives, the latest trends, and in-depth analyses across various medical domains, all in a way that keeps you interested and engaged.
More FAQs by IJCP Editorial Team
Recent FAQs
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please login to comment on this article